The pooled analysis revealed a significant increase in the risk of colorectal cancer among patients receiving GLP-1 RAs (RR: 2.31 [1.82–2.93], I2 = 36%, p < 0.0001), as illustrated in Fig. 2. This evidence concerns the gene GLP1R and colorectal cancer.